Biodesix vs Exagen
Biodesix reported revenue of $88 million in fiscal 2025, 1.3 times Exagen's $67 million in fiscal 2025. Biodesix's revenue grew 24.1% in its latest year, and Exagen's grew 19.6%. Biodesix had an operating margin of -31.5%, against -21.1% at Exagen. Free cash flow was −$24 million at Biodesix and −$14 million at Exagen.
Side by side
| Biodesix | Exagen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $88M | $67M |
| Revenue growth | 24.1% | 19.6% |
| Revenue growth a year, last 5 years | 14.2% | 9.7% |
| Gross margin | — | 58.3% |
| Operating margin | −31.5% | −21.1% |
| Net margin | −39.9% | −30.0% |
| Free cash flow | −$24M | −$14M |
| Free cash flow margin | −26.6% | −21.4% |
| Return on capital | −69.7% | −115.0% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 16.7% | 18.4% |
| Last close | $8.30 | $3.80 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $3.1 million, sold $104,401 | sold $252,640 |
| Piotroski F-score | 3 of 8 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BiodesixExagen
Operating margin
Percent of revenue
BiodesixExagen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BiodesixExagen